



# News Release

## FOR IMMEDIATE RELEASE

### CONTACT:

Martin Williams, SVP & Chief Business Officer  
Dicerna Pharmaceuticals  
(617) 621-8097

Caton Lovett  
Pure Communications  
(910) 232-7166

### **Dicerna Pharmaceuticals to Present at the Second Annual BIO National Venture Conference**

**WATERTOWN, Mass., March 24, 2009** – Dicerna Pharmaceuticals, Inc. ([www.dicerna.com](http://www.dicerna.com)), a second generation RNA interference company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™, today announced that James Jenson, Ph.D., chief executive officer of Dicerna, will present at the Second Annual BIO National Venture Conference on March 31, 2009 at 2:40 p.m. (EDT) at the Sheraton Boston Hotel in Boston, Mass.

#### **About Dicerna**

Dicerna Pharmaceuticals is a private, venture-backed RNAi-focused biopharmaceutical company developing novel therapeutic agents in multiple disease areas based on its proprietary Dicer Substrate Technology platform. Dicerna is developing novel RNAi-based therapies, and related drug delivery systems, that use the engagement of the enzyme Dicer, which is an earlier step in the gene silencing process and a natural initiation point for the RNAi cascade. This distinct biological pathway demonstrates greater potency and a longer duration of action differentiating it from other RNAi approaches and results in the knockdown of expression of a targeted gene in a way that is highly selective and specific. The company believes that its Dicer Substrate Technology is based on intellectual property that is both broadly enabling and distinct from other IP in the field. Dicerna has exclusive, worldwide rights to the Dicer Substrate Technology and has the sole right to grant sublicenses to the full portfolio of Dicer Substrate intellectual property. Dicerna is based in Watertown, Massachusetts. For more information, please visit [www.dicerna.com](http://www.dicerna.com).

###